Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

Konference: 2014 56th ASH Annual Meeting - účast ČR

Kategorie: Maligní lymfomy a leukémie

Téma: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster

Číslo abstraktu: 3064

Autoři: Johannes Drach; MD Huiqiang Huang, PhD; MD Olga S Samoilova; prof. MD Andrew Belch; MD Charles Michael Farber, PhD, FACP; MD Andre Bosly, PhD; MD Jan Novák, Ph.D.; MD Jan Zaucha, Ph.D.; MD Angela Dascalescu, PhD; MD Udomsak Bunworasate; MD Zvenyslava Masliak, PhD; MD Kateryna Vilchevskaya, PhD; MD Tadeusz Robak, PhD.; Lixia Pei, PhD; Brendan Rooney, PhD; MD Helgi van de Velde, PhD; Prof. MD Franco Cavalli, FRCP

Datum přednesení příspěvku: 7. 12. 2014